Company intelligence / Profile preview

Forcefield Therapeutics

London, England, United Kingdomforcefieldtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Forcefield Therapeutics has identified naturally occurring proteins that protect heart cells from dying after a heart attack, aiming to prevent the cascade leading to heart failure. The company’s approach addresses an unmet need, as no current therapies can prevent cardiomyocyte death post-MI. The lead programs are pre-clinical and have not yet reported clinical results.

Therapeutic areas: Cardiovascular
Modalities: Protein therapeutics (cardioprotective proteins)
Industry: Biotech

Drug pipeline

3 assets

Fam3b

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Syncona Investment Management Ltd. (lead investor/partner)Roche Venture Fund (Series A investor)

Beyond the preview

Go deeper on Forcefield Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forcefield Therapeutics.

Explore the full profile